https://mindmedicinelaw.com/briefing/psilocybin-clinical-trial-for-depression-in-lung-cancer-patients-us-2026-20260930-45500The Psychedelic Journalen2026-09-30T15:04:30.513468+00:00Psilocybin Clinical Trial for Depression in Lung Cancer Patients (US, 2026)psilocybin, lung cancer, depression, clinical trial, oncology, palliative care, psychedelic therapy, FDA, insurance coverage, mental healthhttps://mindmedicinelaw.com/briefing/calgary-launches-psychedelic-ptsd-trial-for-partner-violence-survivors-20260929-45400The Psychedelic Journalen2026-09-29T22:04:40.494825+00:00Calgary Launches Psychedelic PTSD Trial for Partner Violence Survivorscalgary psychedelic trial, ptsd partner violence, canada mental health policy, psychedelic-assisted therapy, trauma research, clinical trial canada, health canada special access program, ethical considerations psychedelics, public health trauma, complex ptsd treatmenthttps://mindmedicinelaw.com/briefing/filament-s-pex010-powers-phase-2-psilocybin-ptsd-trial-in-canada-20260929-45237The Psychedelic Journalen2026-09-29T15:04:59.050086+00:00Filament’s PEX010 Powers Phase 2 Psilocybin PTSD Trial in Canadafilament health, pex010, psilocybin, ptsd clinical trial, university of calgary, health canada, gmp-grade psychedelics, canadian psychedelic policy, industry-academic collaboration, psychedelic therapy regulationhttps://mindmedicinelaw.com/briefing/student-mobilization-after-fda-psychedelic-hearing-policy-impact-20260929-45238The Psychedelic Journalen2026-09-29T15:04:45.840616+00:00Student Mobilization After FDA Psychedelic Hearing: Policy Impactfda hearing, psychedelic therapies, student advocacy, drug policy reform, public comment, clinical trial access, regulatory frameworks, grassroots mobilization, equity in research, community oversighthttps://mindmedicinelaw.com/briefing/psilocybin-assisted-therapy-trial-launches-for-depression-in-advanced-lung-cance-20260928-45077The Psychedelic Journalen2026-09-28T22:04:52.897512+00:00Psilocybin-Assisted Therapy Trial Launches for Depression in Advanced Lung Cancer Patients (US)psilocybin-assisted therapy, lung cancer depression, clinical trial 2026, oncology psychedelics, FDA regulation, palliative care, psychedelic research, medical comorbidity, therapeutic risk, policy implicationshttps://mindmedicinelaw.com/briefing/post-psychedelic-difficulties-meta-aggregation-insights-for-counselling-practice-20260927-45287The Psychedelic Journalen2026-09-29T22:04:52.131766+00:00Post-Psychedelic Difficulties: Meta-Aggregation Insights for Counselling Practicepost-psychedelic difficulties, harm reduction, counselling practice, integration support, non-clinical psychedelic use, meta-aggregation, user experiences, public health policy, psychological distress, pluralistic approacheshttps://mindmedicinelaw.com/briefing/network-analysis-of-ketamine-in-trd-pooled-rct-insights-2026-20260926-45338The Psychedelic Journalen2026-09-29T22:05:04.422355+00:00Network Analysis of Ketamine in TRD: Pooled RCT Insights (2026)ketamine, treatment-resistant depression, network analysis, randomized controlled trials, psychedelic research, symptom-level outcomes, precision psychiatry, clinical trial design, depression symptom networkshttps://mindmedicinelaw.com/briefing/ketamine-symptom-level-efficacy-in-trd-pooled-rct-analysis-20260926-45395The Psychedelic Journalen2026-09-29T22:04:26.931089+00:00Ketamine Symptom-Level Efficacy in TRD: Pooled RCT Analysisketamine, treatment-resistant depression, symptom-level analysis, randomized controlled trials, network analysis, psychiatric policy, regulatory implications, clinical trial design, personalized psychiatryhttps://mindmedicinelaw.com/briefing/fda-debars-jeffrey-thies-for-10-years-implications-for-drug-import-compliance-20260925-44714The Psychedelic Journalen2026-09-28T22:06:32.073665+00:00FDA Debars Jeffrey Thies for 10 Years: Implications for Drug Import Compliancefda debarment, drug import violations, psychedelic research compliance, controlled substances, supply chain risk, federal food drug and cosmetic act, clinical trial regulation, counterfeit pharmaceuticals, legal enforcement, us drug policyhttps://mindmedicinelaw.com/briefing/prolonged-psychological-distress-after-lsd-case-report-insights-for-clinical-and-20260924-44724The Psychedelic Journalen2026-09-29T15:05:30.496413+00:00Prolonged Psychological Distress After LSD: Case Report Insights for Clinical and Public Health Policylsd adverse effects, psychedelic harm reduction, clinical trial screening, psychiatric vulnerability, set and setting, alcohol and psychedelics, case report, public health policyhttps://mindmedicinelaw.com/briefing/no-subacute-ketamine-effect-on-reward-processing-implications-for-trial-design-20260924-44774The Psychedelic Journalen2026-09-29T15:05:21.578396+00:00No Subacute Ketamine Effect on Reward Processing: Implications for Trial Designketamine, reward processing, fMRI, clinical trial design, subacute effects, healthy adults, mood disorders, pharmacokinetics, neural biomarkershttps://mindmedicinelaw.com/briefing/temporal-structure-modulates-psychedelic-experience-new-evidence-20260924-44794The Psychedelic Journalen2026-09-29T15:05:09.624270+00:00Temporal Structure Modulates Psychedelic Experience: New Evidencepsychedelic experience, temporal structure, clinical trial design, neuroscience, subjective effects, intervention timing, therapeutic protocols, FDA, research methodologyhttps://mindmedicinelaw.com/briefing/ketamine-use-during-spine-surgery-implications-for-opioid-reduction-policies-20260923-44885The Psychedelic Journalen2026-09-29T15:06:03.930269+00:00Ketamine Use During Spine Surgery: Implications for Opioid Reduction Policiesketamine, lumbar spine surgery, chronic opioid use, opioid-use disorder, perioperative pain management, retrospective study, policy implications, clinical protocols, enhanced recovery, opioid stewardshiphttps://mindmedicinelaw.com/briefing/trehalose-from-psilocybe-preclinical-antidepressant-effects-20260923-44731The Psychedelic Journalen2026-09-29T15:05:52.654662+00:00α,α-Trehalose from Psilocybe: Preclinical Antidepressant Effectsα,α-trehalose, psilocybe cubensis, preclinical antidepressant, anxiolytic effects, 5-HT1A receptor, non-psychedelic metabolites, mental health therapeutics, drug development, regulatory implicationshttps://mindmedicinelaw.com/briefing/attachment-based-interventions-and-intergenerational-substance-use-risk-implicat-20260923-44743The Psychedelic Journalen2026-09-29T15:05:40.123328+00:00Attachment-Based Interventions and Intergenerational Substance Use Risk: Implications for Policy and Practiceattachment-based interventions, parental substance use, intergenerational risk, care-experienced populations, public health policy, family-oriented treatment, attachment security, substance use prevention, systematic review, child welfarehttps://mindmedicinelaw.com/briefing/optimi-health-s-psilocybin-milestone-phase-2-mdd-trial-and-trd-supply-in-canada-20260923-45240The Psychedelic Journalen2026-09-29T15:04:33.323104+00:00Optimi Health's Psilocybin Milestone: Phase 2 MDD Trial and TRD Supply in Canadaoptimi health, psilocybin, canada, health canada, gmp production, phase 2 clinical trial, major depressive disorder, treatment-resistant depression, psychedelic supply chain, regulatory policyhttps://mindmedicinelaw.com/briefing/early-data-from-uk-s-first-pediatric-ketamine-uropathy-clinic-20260922-45483The Psychedelic Journalen2026-09-30T15:05:32.932803+00:00Early Data from UK’s First Pediatric Ketamine Uropathy Clinicketamine-induced uropathy, pediatric substance misuse, uk public health, youth drug trends, clinical guidelines, recreational ketamine, sociodemographic risk factors, policy response, harm reduction, adolescent healthhttps://mindmedicinelaw.com/briefing/patient-factors-and-subanesthetic-ketamine-in-pacu-clinical-insights-20260922-45074The Psychedelic Journalen2026-09-30T15:05:18.945170+00:00Patient Factors and Subanesthetic Ketamine in PACU: Clinical Insightssubanesthetic ketamine, postanesthesia care unit, perioperative pain management, patient selection, risk stratification, psychiatric comorbidity, opioid tolerance, clinical protocols, pharmacovigilancehttps://mindmedicinelaw.com/briefing/debate-over-subjective-measures-in-ketamine-and-psilocybin-trials-20260922-44734The Psychedelic Journalen2026-09-30T15:05:07.286684+00:00Debate Over Subjective Measures in Ketamine and Psilocybin Trialssubjective effects, ketamine, psilocybin, clinical trials, measurement tools, meta-analysis, regulatory science, psychotherapy, FDA, methodological rigorhttps://mindmedicinelaw.com/briefing/methodological-critique-of-ketamine-subjective-effects-studies-20260922-44735The Psychedelic Journalen2026-09-30T15:04:55.987731+00:00Methodological Critique of Ketamine Subjective Effects Studiesketamine, subjective effects, methodological flaws, psychedelic-assisted therapy, clinical trial design, meta-analysis, research standards, FDA, validated measures, regulatory implicationshttps://mindmedicinelaw.com/briefing/comorbidity-of-bipolar-disorder-in-cluster-headache-clinical-and-research-implic-20260922-44736The Psychedelic Journalen2026-09-30T15:04:43.690143+00:00Comorbidity of Bipolar Disorder in Cluster Headache: Clinical and Research Implications (Netherlands, 2026)cluster headache, bipolar disorder, comorbidity, psychedelic clinical trials, psychiatric screening, familial aggregation, illicit drug use, patient selection, netherlands, circadian rhythmhttps://mindmedicinelaw.com/briefing/ptsd-fear-circuit-insights-implications-for-psychedelic-interventions-20260922-44745The Psychedelic Journalen2026-09-29T22:06:21.361275+00:00PTSD Fear Circuit Insights: Implications for Psychedelic Interventionsptsd neural circuitry, fear circuit, exposure therapy, propranolol, psychedelic-assisted therapy, mdma, psilocybin, treatment gaps, biomarkers, clinical trial designhttps://mindmedicinelaw.com/briefing/psilocybin-ethocybin-heighten-aversive-memory-in-stressed-mice-20260922-44764The Psychedelic Journalen2026-09-29T22:06:09.017008+00:00Psilocybin, Ethocybin Heighten Aversive Memory in Stressed Micepsilocybin, ethocybin, aversive memory, preclinical study, chronic social stress, pavlovian conditioning, psychedelic therapy, emotional processing, clinical trial risk, neuroplasticityhttps://mindmedicinelaw.com/briefing/glutamatergic-mechanisms-in-depression-schizophrenia-and-addiction-implications--20260922-44767The Psychedelic Journalen2026-09-29T22:05:57.086489+00:00Glutamatergic Mechanisms in Depression, Schizophrenia, and Addiction: Implications for Psychedelic Researchglutamate, psychedelics, depression, schizophrenia, addiction, biomarkers, clinical trial design, ketamine, translational neurosciencehttps://mindmedicinelaw.com/briefing/self-inquiry-as-a-neurophenomenological-tool-implications-for-psychedelic-resear-20260922-44733The Psychedelic Journalen2026-09-29T22:05:42.194572+00:00Self-Inquiry as a Neurophenomenological Tool: Implications for Psychedelic Researchself-inquiry, consciousness research, neurophenomenology, psychedelic therapy, nondual awareness, minimal self, clinical trials, advaita vedanta, subjective experiencehttps://mindmedicinelaw.com/briefing/dmt-harmine-eeg-signatures-implications-for-psychedelic-biomarkers-20260922-44829The Psychedelic Journalen2026-09-29T22:05:28.959464+00:00DMT/Harmine EEG Signatures: Implications for Psychedelic Biomarkersdmt, harmine, eeg biomarkers, psychedelic research, clinical trial design, regulatory science, ayahuasca, neurophysiology, biomarker developmenthttps://mindmedicinelaw.com/briefing/methodological-challenges-in-assessing-ketamine-s-subjective-effects-20260922-44889The Psychedelic Journalen2026-09-29T15:06:17.839258+00:00Methodological Challenges in Assessing Ketamine's Subjective Effectsketamine subjective effects, clinical trial methodology, psychedelic research, patient-reported outcomes, regulatory science, measurement standardization, FDA, EMA, psychometrics, risk-benefit analysishttps://mindmedicinelaw.com/briefing/fda-public-hearing-on-psychedelic-therapies-implications-for-us-policy-20260922-45078The Psychedelic Journalen2026-09-28T22:04:37.749037+00:00FDA Public Hearing on Psychedelic Therapies: Implications for US Policyfda, psychedelic therapies, public hearing, us drug policy, clinical trials, regulatory guidance, rescheduling, risk management, expanded access, post-market surveillancehttps://mindmedicinelaw.com/briefing/phenomenological-frameworks-in-psychedelic-therapy-implications-for-research-and-20260921-44741The Psychedelic Journalen2026-09-30T15:06:17.868736+00:00Phenomenological Frameworks in Psychedelic Therapy: Implications for Research and Ethicsphenomenology, psychedelic therapy, merleau-ponty, mystical experience, embodiment, clinical trial design, ethics, depression, subjective experience, regulatory policyhttps://mindmedicinelaw.com/briefing/serotonin-1b-receptor-new-target-in-depression-anxiety-research-20260921-44830The Psychedelic Journalen2026-09-30T15:06:04.770646+00:00Serotonin 1B Receptor: New Target in Depression & Anxiety Researchserotonin 1b receptor, depression treatment, anxiety therapy, psychedelic research, serotonergic pathways, clinical trials, drug development, mental health policy, regulatory sciencehttps://mindmedicinelaw.com/briefing/timing-deficits-in-schizophrenia-neurobiological-insights-and-psychedelic-resear-20260921-44738The Psychedelic Journalen2026-09-30T15:05:47.518340+00:00Timing Deficits in Schizophrenia: Neurobiological Insights and Psychedelic Research Implicationsschizophrenia, time processing, dopaminergic dysfunction, gabaergic system, nmda receptor, psychedelic research, biomarkers, clinical trials, cognitive symptoms, neurobiologyhttps://mindmedicinelaw.com/briefing/ketamine-s-impact-on-gaba-and-glutamate-in-depression-meta-analysis-insights-20260921-45356The Psychedelic Journalen2026-09-29T22:05:17.527724+00:00Ketamine’s Impact on GABA and Glutamate in Depression: Meta-Analysis Insightsketamine, depression, gaba, glutamate, magnetic resonance spectroscopy, biomarkers, rapid-acting antidepressants, clinical trials, fda regulation, psychiatric drug developmenthttps://mindmedicinelaw.com/briefing/toxicokinetics-of-dmt-derivatives-new-human-and-zebrafish-data-20260921-44747The Psychedelic Journalen2026-09-28T22:05:21.559866+00:00Toxicokinetics of DMT Derivatives: New Human and Zebrafish Datadmt derivatives, toxicokinetics, psychedelic metabolism, forensic toxicology, clinical trial design, drug-drug interactions, novel tryptamines, zebrafish embryo model, cytochrome p450, plasma protein bindinghttps://mindmedicinelaw.com/briefing/mania-and-rhabdomyolysis-linked-to-chronic-psilocybin-use-clinical-and-policy-le-20260921-44788The Psychedelic Journalen2026-09-28T22:05:07.903477+00:00Mania and Rhabdomyolysis Linked to Chronic Psilocybin Use: Clinical and Policy Lessonspsilocybin safety, mania, rhabdomyolysis, chronic psychedelic use, dosing guidelines, adverse event reporting, public health policy, clinical trial limitations, psychedelic riskshttps://mindmedicinelaw.com/briefing/ayahuasca-and-early-life-stress-preclinical-insights-for-neuroscience-and-policy-20260919-44832The Psychedelic Journalen2026-09-30T15:06:29.249826+00:00Ayahuasca and Early-Life Stress: Preclinical Insights for Neuroscience and Policyayahuasca, early-life stress, preclinical research, psychedelic neuroscience, rat model, behavioral outcomes, neurochemical effects, clinical trial design, policy implications, translational challengeshttps://mindmedicinelaw.com/briefing/chemical-restraint-in-u-s-custody-trends-outcomes-and-policy-shifts-2022-2025-20260919-44877The Psychedelic Journalen2026-09-28T22:05:32.441686+00:00Chemical Restraint in U.S. Custody: Trends, Outcomes, and Policy Shifts (2022–2025)chemical restraint, ketamine in custody, law enforcement policy, psychoactive agents, emergency medicine, civil liberties, clinical outcomes, policy reform, adverse events, oversight standardshttps://mindmedicinelaw.com/briefing/employment-risks-in-psychedelic-chronic-pain-trials-policy-and-clinical-implicat-20260918-44795The Psychedelic Journalen2026-09-28T22:05:52.416257+00:00Employment Risks in Psychedelic Chronic Pain Trials: Policy and Clinical Implicationspsychedelic clinical trials, chronic pain, employment risks, workplace drug testing, informed consent, policy implications, trial design, legal protections, participant safety, regulatory guidancehttps://mindmedicinelaw.com/briefing/chronic-ketamine-misuse-multi-organ-risks-and-clinical-gaps-20260918-44753The Psychedelic Journalen2026-09-28T22:05:42.874508+00:00Chronic Ketamine Misuse: Multi-Organ Risks and Clinical Gapsketamine misuse, multi-organ toxicity, neuropsychiatric complications, ketamine-induced uropathy, cardiac remodeling, respiratory risk, clinical management, dependence treatment gap, public health policyhttps://mindmedicinelaw.com/briefing/ketamine-safety-in-psychosis-high-risk-groups-new-evidence-and-policy-implicatio-20260917-44818The Psychedelic Journalen2026-09-28T22:06:05.673006+00:00Ketamine Safety in Psychosis High-Risk Groups: New Evidence and Policy Implicationsketamine, psychosis risk, clinical high risk, psychedelic therapy, screening protocols, adverse events, clinical trials, public health policy, NMDA antagonist, psychiatric safetyhttps://mindmedicinelaw.com/briefing/stronger-masking-urged-in-psychedelic-trials-policy-and-research-impact-20260916-44824The Psychedelic Journalen2026-09-28T22:06:17.068446+00:00Stronger Masking Urged in Psychedelic Trials: Policy and Research Impactpsychedelic trials, masking, blinding, clinical trial design, regulatory standards, bias in research, FDA, IRB requirements, active placebo, psychedelic research